NAD+ Precursor Supplementation in Friedreich's Ataxia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-17

Study Completion Date

2022-05-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to test the safety and tolerability of short-term therapy with a nicotinamide adenine dinucleotide (NAD+) precursor (MIB-626) in adults with Friedreich's Ataxia (FA) without overt heart failure and with a left ventricular ejection fraction ≥ 40%. A key secondary objective is to test the effects of MIB-626 on cardiac and skeletal muscle bioenergetics.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NAD+ and Exercise in FA

NCT04192136

Friedreich Ataxia 1

ACTIVE_NOT_RECRUITING NA

A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

NCT07180355

Friedreich's Ataxia (FA)

RECRUITING PHASE1

Methylprednisolone Treatment of Friedreich Ataxia

NCT02424435

Friedreich Ataxia

COMPLETED EARLY_PHASE1

Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III

NCT00439569

Spinal Muscular Atrophy Type II Spinal Muscular Atrophy Type III

TERMINATED PHASE1/PHASE2

Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia

NCT05573698

Friedreich Ataxia

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary focus for this protocol is safety and tolerability. We will systematically assess for adverse events using a safety monitoring uniform report form. We will also use cardiac 31-Phosphorus-Magnetic Resonance Spectroscopy (MRS) to measure the Phosphocreatine(PCr)/Adenosine triphosphate (ATP)- γ ratio before and after treatment with MIB-626. In addition, if time permits we will use proton (1H)-MRS to measure skeletal muscle nicotinamide adenine dinucleotide (NAD+) before and after treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Friedreich Ataxia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Open Label, 14 Days (+/- 2 Days)

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open Label - MIB-626

MIB-626

Group Type OTHER

MIB-626

Intervention Type DRUG

Two (2) 500 mg Tablets, By Mouth, Daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MIB-626

Two (2) 500 mg Tablets, By Mouth, Daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Molecular diagnosis of Friedreich's Ataxia (FA).
* Males and females, ages 18 years to \< 65 years.

Exclusion Criteria

* Known sensitivity to nicotinamide-containing compounds.
* Concurrent use of Vitamin B3 supplements and/or any medications likely to increase risk of MIB-626 toxicity.
* HgbA1c \> (great than or equal to) 8.5% and or Diabetes Mellitus (DM) requiring insulin or insulin secretagogue.
* Kidney disease (Estimated Glomerular Filtration Rate (eGFR) \< 60 ml/min/1.73 m2) using serum creatinine and MDRD equation. The eGFR levels will be calculated using the Modified Diet in Renal Disease Study (MDRD) equation, which is the equation used by the Children's Hospital Of Philadelphia laboratory.
* Liver disease (Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) \> 3 x Upper Limit of Normal)
* Severe co-existing cardiac disease (Ejection Fraction (EF) \< 40%, known arrhythmia) as demonstrated by an echocardiogram within 12 months of screening.
* Any contraindication to MRI, including spinal rods (related to unknown safety considerations for cardiac 31-Phosphorus -MRS).
* Use of any investigational agent within 4 weeks of enrollment.
* Females: Pregnant/lactating or planning to become pregnant during their participation.
* Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No